Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07680790 Izalontamab Brengitecan EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07680790 clinical trial report covering Izalontamab Brengitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07680088 Pembrolizumab squamous cell carcinoma of the anus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07680088 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07681167 Faricimab Central Serous Chorioretinopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07681167 clinical trial report covering Faricimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262589 DR-10624 Hypertriglyceridemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262589 clinical trial report covering DR-10624, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262497 YZD-27 Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262497 clinical trial report covering YZD-27, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262592 XiaoErYinLian Granules Acute upper respiratory infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262592 clinical trial report covering XiaoErYinLian Granules, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031260281 Oremepermin alfa Androgen-Insensitivity Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
JPRN-jRCT2031260281 clinical trial report covering Oremepermin alfa, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2061260037 Umedaptanib pegol Achondroplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
JPRN-jRCT2061260037 clinical trial report covering Umedaptanib pegol, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600127737 Topiramate Hyperuricemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
ChiCTR2600127737 clinical trial report covering Topiramate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600127720 Serplulimab Colonic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
ChiCTR2600127720 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07684820 XH-S004 Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684820 clinical trial report covering XH-S004, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07684326 Dapagliflozin Hepatic ascites Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684326 clinical trial report covering Dapagliflozin, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.